Cis-Diamminedichloroplatinum Ii
Gastroesophageal Junction Adenocarcinoma
Explore 110 assets in Gastroesophageal Junction Adenocarcinoma →Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Shenyang Sunshine Pharmaceutical Co., LTD.
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
63High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07233850CT.gov A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers | — | Not Yet Recruiting | — | — | — |
NCT05945823CT.gov Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04882241CT.gov Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension | — | Completed | — | — | — |
NCT04389632CT.gov A Study of Sigvotatug Vedotin in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT04210115CT.gov Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) | — | Active Not Recruiting | — | — | — |
NCT03615326CT.gov Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) | — | Completed | — | — | — |
NCT03221426CT.gov Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) | — | Completed | — | — | — |
NCT02335411CT.gov A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Gastroesophageal Junction Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cis-Diamminedichloroplatinum Ii (this asset) | Shenyang Sunshine Pharmaceutical Co., LTD. | P3 | BB · 66 |
| Irinotecan | AstraZeneca | P3 | BBB |
| Cyclophosphamide | Beijing Biotech | P3 | BB |
| Fluorouracilum | Alliance for Clinical Trials in Oncology | P3 | BB |
| Pembrolizumab | Eikon Therapeutics | P3 | BB |
| Capecitabine | I-Mab Biopharma US Limited | P3 | BB |
| Oxaliplatin | Alliance for Clinical Trials in Oncology | P3 | BB |
| Levofolinic Acid | Merck Sharp & Dohme LLC | P3 | BB |
| Disitamab Vedotin | BeOne Medicines | P2 | BB |
+42 more in the Gastroesophageal Junction Adenocarcinoma cohort
Other indications for Cis-Diamminedichloroplatinum Ii
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Squamous Cell Lung Carcinoma | — | P4 | BBB · 78 |
| Primary Peritoneal Carcinoma | — | P3 | BBB · 77 |
| Adenocarcinoma | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cis-Diamminedichloroplatinum Ii in Gastroesophageal Junction Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cis-diamminedichloroplatinum-ii-gastroesophageal-junction-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →